Abnova (Taiwan) Corporation

Equities

4133

TW0004133004

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 03:30:00 26/06/2024 am IST			5-day change	1st Jan Change
34.05 ^TWD	+1.95%		+1.79%	-2.99%

09/05	Abnova Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
08/05	Abnova Corporation Announces Establishment of Risk Management Committee	CI

PharmaJet and Abnova Announce Partner to Develop and Deliver COVID-19 mRNA Vaccine using Needle-free Injection Technology

May 19, 2020 at 07:40 pm IST

PharmaJet® announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation. Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of their mRNA candidate.

Latest news about Abnova (Taiwan) Corporation

Abnova Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Abnova Corporation Announces Establishment of Risk Management Committee	08/05	CI
Abnova Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Abnova Corporation Approves Cash Dividend for the Year Ended December 31, 2023, Payable on June 27, 2024	20/02	CI
Abnova Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Abnova Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/23/03	CI
Abnova Corporation Announces Dividend Distribution for 2022, Payment on 5 July 2023	31/23/31	CI
Abnova Corporation Elects Members of the Company's Remuneration Committee	15/23/15	CI
Abnova Corporation Elects Members of the Company's Audit Committee	15/23/15	CI
Abnova Corporation Elects Board Members	15/23/15	CI
Abnova Corporation Approves Dividend Distribution for the Year 2022	15/23/15	CI
Abnova Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Abnova Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Abnova Corporation Announces Change of President	24/23/24	CI
Abnova Corporation Approves Dividend Distribution for the Year 2022	24/23/24	CI
Abnova Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Abnova Corporation(TWSE:4133) dropped from S&P Global BMI Index	19/22/19	CI
Abnova Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/22/10	CI
Abnova Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	05/22/05	CI
Abnova Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	21/22/21	CI
Abnova Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	11/21/11	CI
Abnova Taiwan Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	11/21/11	CI
Abnova Taiwan Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	03/21/03	CI
Abnova Taiwan Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	30/21/30	CI
Abnova Taiwan Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	11/20/11	CI

Chart Abnova (Taiwan) Corporation

Duration

Period

More charts

Company Profile

ABNOVA (TAIWAN) CORPORATION is a Taiwan-based company principally engaged in the manufacturing and sales of antibodies and proteins. The Company's products mainly include monoclonal antibodies, polyclonal antibodies, protein fragments, full-length proteins, active proteins, antibody pairs, fluorescence in situ hybridization probe and others. The Company's monoclonal and polyclonal antibodies are primarily applied in medical testing reagents, agricultural testing, industrial purification, medical treatment and other fields. Its proteins are mainly applied in medical testing reagents, agricultural testing, medical treatment, protein engineering and other fields. Its products are mainly traded in Taiwan, Americas and Europe.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABNOVA (TAIWAN) CORPORATION	-2.99%	6.22Cr
VERTEX PHARMACEUTICALS INCORPORATED	+16.38%	12TCr
REGENERON PHARMACEUTICALS, INC.	+21.64%	12TCr
ARGENX SE	+22.18%	2.7TCr
BIONTECH SE	-21.36%	2.04TCr
GENMAB A/S	-16.89%	1.64TCr
BEIGENE, LTD.	-18.97%	1.59TCr
WUXI APPTEC CO., LTD.	-44.74%	1.56TCr
SAREPTA THERAPEUTICS, INC.	+62.48%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+3.26%	1.36TCr

Bio Therapeutic Drugs